PRNewswire-PRWeb June 8, 2026
HepQuant Achieves College of American Pathologists (CAP) Accreditation Demonstrating Commitment to Laboratory Excellence
PRESS RELEASE HepQuant Achieves College of American Pathologists (CAP) Accreditation Demonstrating Commitment to Laboratory Excellence Denver, CO – June 8, 2026 – HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announced that its laboratory has achieved accreditation from the College of American Pathologists (CAP), recognizing…
PRNewswire-PRWeb | May 27, 2026
Three Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO®
Three Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO® PRNewswire-PRWeb DENVER, Colo., May 27, 2026 — HepQuant, LLC announced the presentation of three studies at the 2026 Congress of the European Association for the Study of the Liver (EASL), showcasing the clinical and research value…
PRNewswire-PRWeb | May 5, 2026
2026 DDW Oral Presentation: HepQuant DuO® Disease Severity Index (DSI) Outperforms Child-Pugh and MELD Scores in Predicting Risk of Esophageal Varices
Chicago, IL – May 5, 2026 – HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is excited to announce an oral presentation at Digestive Disease Week (DDW) 2026. Dr. Mitchell Shiffman1 will present data findings and discuss HepQuant DuO® as part of the DDW session:…
PRNewswire-PRWeb January 12, 2026
2026 MASH-TAG Oral Presentation: HepQuant DuO® Reveals Functional and Physiological Heterogeneity to Support Enhanced Clinical Trial Design
“HepQuant DuO is the ideal noninvasive test of liver health with clinical validation data confirming effective characterization of disease severity, tracking of disease progression and treatment impact.”, stated Dr. Gregory T. Everson, Chief Executive Officer of HepQuant. “HepQuant is committed to bringing this important quantitative tool to healthcare providers to transform liver health and improve patient management.”In The News
June 15, 2026
HepQuant Sponsors Team at the Transplant Games of America
HepQuant is proud to sponsor Team Rocky Mountain (TRM), a local team participating in the 2026 Transplant Games, taking place June 18–23 in Denver. Representing 145 transplant recipients, living donors, donor families, and supporters from across the Rocky Mountain region, TRM embodies the strength and resilience of the transplant community. The Transplant Games are a six-day, biennial festival celebrating the gift of organ, tissue, and eye donation through more than 20 athletic and recreational events. HepQuant is honored to support this inspiring team and help raise awareness of the life-saving impact of donation and transplantation.Dr. Greg Everson Speaks at PSC Forum 9 in Washington, DC
Dr. Greg T. Everson presented at the annual PSC Forum 9 in Washington, DC, sharing how the oral cholate challenge test can help clinicians more accurately assess disease severity in patients with primary sclerosing cholangitis (PSC). Click here to see his presentation.